Glaxo-Wellcome has clarified its position in regards to its decision to delay the trials for Dutasteride (GI198,745).  In recent emails to visitors who corresponded with Glaxo, they have made their position clear with the following statement sent to concerned hairloss sufferers:

"Glaxo Wellcome remains committed to both the product and the disease area   The company will to reschedule the start date of the GI19874 AGA Phase III programme in February 2000.  GI198745 is also being developed for benign prostatic hyperplasia (BPH).  This program is progressing according to plans and will not be impacted by the decision to reschedule the androgenetic alopecia program."

Regrowth.com is now in touch with a spokesperson at Glaxo-Wellcome regarding this who will be keeping Regrowth informed of future decisions regarding Dutasteride, and we will be updating information on the site regarding this as it becomes available.

According to Mary Ann Rhyne, a spokesperson for Glaxo-Wellcome, "Glaxo-wellcome remains committed to the product in this disease area. A decision... is to be taken in February 2000."

According to Ms. Rhyne in regards to our inquiry, GI198,745 has not yet been submitted to the FDA for approval for Benign Prostatic Hyperplasia (BPH), the first form in which it will become available.  Regrowth.com will also be following the BPH version as it moves forward in the approval process and expects to keep viewers informed of its status.

Ms. Rhyne was very helpful and positive in our conversation regarding GI198,745, and it is this person's opinion that her attitude reflects a commitment by Glaxo-Wellcome towards this product and keeping hairloss sufferers informed of its status.

Hot Links:

• Regrowth's GI198,745 Information Page
• Keep Me Updated on Stories Like This!
• Get Free Hairloss Information from Doctors and Companies in My Area